Nikos Afratis
Cited by
Cited by
Glycosaminoglycans: key players in cancer cell biology and treatment
N Afratis, C Gialeli, D Nikitovic, T Tsegenidis, E Karousou, AD Theocharis, ...
The FEBS journal 279 (7), 1177-1197, 2012
A guide to the composition and functions of the extracellular matrix
NK Karamanos, AD Theocharis, Z Piperigkou, D Manou, A Passi, ...
The FEBS journal 288 (24), 6850-6912, 2021
Syndecans–key regulators of cell signaling and biological functions
NA Afratis, D Nikitovic, HAB Multhaupt, AD Theocharis, JR Couchman, ...
The FEBS journal 284 (1), 27-41, 2017
Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans
SS Skandalis, N Afratis, G Smirlaki, D Nikitovic, AD Theocharis, ...
Matrix Biology 35, 182-193, 2014
Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells
P Bouris, SS Skandalis, Z Piperigkou, N Afratis, K Karamanou, AJ Aletras, ...
Matrix Biology 43, 42-60, 2015
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine
AD Theocharis, SS Skandalis, T Neill, HAB Multhaupt, M Hubo, H Frey, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1855 (2), 276-300, 2015
Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion
K Kouvidi, A Berdiaki, D Nikitovic, P Katonis, N Afratis, VC Hascall, ...
Journal of Biological Chemistry 286 (44), 38509-38520, 2011
Syndecans as modulators and potential pharmacological targets in cancer progression
D Barbouri, N Afratis, C Gialeli, DH Vynios, AD Theocharis, N Karamanos
Frontiers in oncology 4, 74118, 2014
Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin‐like growth factor receptor in the expression of cell surface …
AI Tsonis, N Afratis, C Gialeli, MI Ellina, Z Piperigkou, SS Skandalis, ...
The FEBS journal 280 (10), 2248-2259, 2013
The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: applications to drug discovery
NA Afratis, M Klepfish, NK Karamanos, I Sagi
Advanced drug delivery reviews 129, 4-15, 2018
LOXL2 inhibition paves the way for macrophage-mediated collagen degradation in liver fibrosis
M Klepfish, T Gross, M Vugman, NA Afratis, S Havusha-Laufer, ...
Frontiers in Immunology 11, 480, 2020
IGF-IR cooperates with ERá to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules
NA Afratis, P Bouris, SS Skandalis, HA Multhaupt, JR Couchman, ...
Scientific reports 7 (1), 40138, 2017
Emerging insights into the role of matrix metalloproteases as therapeutic targets in fibrosis
NA Afratis, M Selman, A Pardo, I Sagi
Matrix Biology 68, 167-179, 2018
The role of heparins and nano-heparins as therapeutic tool in breast cancer
NA Afratis, K Karamanou, Z Piperigkou, DH Vynios, AD Theocharis
Glycoconjugate journal 34, 299-307, 2017
Biochemical and toxicological evaluation of nano-heparins in cell functional properties, proteasome activation and expression of key matrix molecules
Z Piperigkou, K Karamanou, NA Afratis, P Bouris, C Gialeli, CLR Belmiro, ...
Toxicology letters 240 (1), 32-42, 2016
Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma
G Heidari-Hamedani, RR Vivès, A Seffouh, NA Afratis, A Oosterhof, ...
Cellular Signalling 27 (10), 2054-2067, 2015
Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules
S S Skandalis, A J Aletras, C Gialeli, A D Theocharis, N Afratis, ...
Current molecular medicine 12 (8), 1068-1082, 2012
FACE analysis as a fast and reliable methodology to monitor the sulfation and total amount of chondroitin sulfate in biological samples of clinical importance
E Karousou, A Asimakopoulou, L Monti, V Zafeiropoulou, N Afratis, ...
Molecules 19 (6), 7959-7980, 2014
Novel approaches for extracellular matrix targeting in disease treatment
NA Afratis, I Sagi
The Extracellular Matrix: Methods and Protocols, 261-275, 2019
Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol 4: 4
D Barbouri, N Afratis, C Gialeli, DH Vynios, AD Theocharis, ...
The system can't perform the operation now. Try again later.
Articles 1–20